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Hereditary diffuse leukoencephalopathy with spheroids (HDLS) in humans is a rare autosomal dominant
disease characterized by giant neuroaxonal swellings (spheroids) within the CNS white matter. Symptoms
are variable and can include personality and behavioural changes. Patients with this disease have mutations
in the protein kinase domain of the colony-stimulating factor 1 receptor (CSF1R) which is a tyrosine kinase
receptor essential for microglia development. We investigated the effects of these mutations on Csf1r
signalling using a factor dependent cell line. Corresponding mutant forms of murine Csf1r were expressed
on the cell surface at normal levels, and bound CSF1, but were not able to sustain cell proliferation. Since
Csf1r signaling requires receptor dimerization initiated by CSF1 binding, the data suggest a mechanism for
phenotypic dominance of the mutant allele in HDLS.
H
ereditary diffuse leukoencephalopathy with spheroids (HDLS) is an autosomal-dominant neurodegen-
erative condition with rather variable penetrance. A recent study identified mutations in the colony-
stimulating factor 1 receptor (CSF1R) in multiple families with this disorder1. Subsequently, CSF1R
mutations were identified in a related disorder termed pigmented orthochromatic leukodystrophy2. CSF1R
signalling is required for the generation of the majority of mature macrophages3, including the microglia of
the brain4. CSF1-dependent microglial activation has been implicated in neural damage in a model of Charcot-
Marie-Tooth disease5. The authors of the recent report suggest that the causal mutations in CSF1R result in a loss
of function, although there was no evidence of altered CSF1R levels or phosphorylation state in blood or brain
samples from HDLS patients. Conversely, in vitro analysis of transfected HeLa cells resulted in no detectable
autophosphorylation in three HDLS CSF1Rmutations. The authors suggest that the presence of wild type CSF1R
in the heterozygous individuals as the cause of this discrepancy1. Heterozygousmutation ofCsf1r inmice does not
generate any phenotype, suggesting that haploinsufficiency is an unlikely explanation for the dominant inher-
itance in HDLS. An alternative suggestion was that in patients the products of the mutant allele might assemble
into heterodimers with wild-type protein and have a dominant negative effect.
CSF1R is a type III receptor tyrosine kinase belonging to the platelet-derived growth factor (PDGF) receptor
family whose members include PDGF-a and –b, the FMS-like tyrosine kinase 3 (FLT3) and the receptor for stem
cell factor (c-KIT)6. These proteins have similar structures consisting of five immunoglobulin-like domains, a
transmembrane domain, a juxtamembrane domain (JM) and a protein kinase domain divided in two by an insert
domain (KID)7. Protein kinase domains are structurally conserved and as key regulators ofmost cellular pathways
are frequently associated with disease and are often oncogenic8. Mutations in the kinase domains of PDGF-a and
c-KIT result in increased receptor dimerization leading to gastrointestinal tumours and mastocytosis (reviewed
in9) whilst FLT3 gain of function mutations are often found in acute myeloid leukemia10. Overexpression of
CSF1R has been reported in a number of diseases including myeloid malignancies11.
CSF1R, like many related tyrosine kinase receptors, exists in an autoinhibited state, stabilized by the JM
domain12,13. Upon activation, the receptor dimerizes which results in autophosphorylation of a number of
tyrosine residues in the intracellular domain and leads to recruitment of signalling molecules and ultimately
internalization of the receptor. Yu et al14. generated a CSF1R in which all 6 major tyrosines involved in signalling
were replaced by phenylalanine. Restoration of Y807 (Y809 in human) produced a receptor that was able to
support ligand independent proliferation in a factor dependent cell line15. Three recent HDLS case reports have
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In this study, we chose four HDLSmutations and created express-
ion plasmids introducing the corresponding mutation in murine
Csf1r. All mutated residues are highly conserved and are located in
the protein kinase (PTK) domain. In addition to these, we examined
four other mutations. We included a mutation (K584E) in the con-
served N terminal region of the PTK domain that has not previously
been implicated in autoinhibition as well as a mutation in the activa-
tion loop (R814P). As a positive control, a kinase-defective receptor,
K614R, with a mutation in the ATP-binding site was created19. In
addition, we created a double mutation within the catalytic site
(V661I/T663A). The mutant proteins were expressed in IL-3-
dependent Ba/F3 cells. Although these cells were originally referred
to as pro-B cells, they express the myeloid-specific F4/80 and CD11b
antigens andmay therefore be an appropriate model system in which
to investigate CSF1 signalling20. We report that the mutations iden-
tified in HDLS1 as well as the K614R mutant were unable to sustain
growth in CSF1. They were nevertheless expressed on the cell surface
at the same level as the wild-type receptor and could be internalized
in response to addition of CSF1. Csf1r signalling was intact in R814P,
V661I/T663A and K584E whilst the latter two mutations displayed
varying degrees of constitutive activity. We thus confirm that muta-
tions of CSF1R in HDLS are loss of function and that the use of the
Ba/F3 factor dependent cell line is an invaluable tool for assessing the
effects of further Csf1r mutations in vitro.
Results
The protein kinase domain of human and mouse CSF1R is highly
conserved. In order to examine the CSF1Rmutations found inHDLS
the equivalent murine mutations were produced. An overlay of the
protein kinase domains of human andmouse CSF1R emphasizes the
highly conserved nature of this protein (Figure 1). The kinase insert
domain is not required for kinase activity21 and the highlighted
mutations did not affect the structure of the protein kinase domain
when modeled in YASARA (data not shown).
Csf1rmutants found inHDLS do not signal when expressed in Ba/
F3 cells. Rademakers and colleagues1 suggested that the CSF1Rmuta-
tions are effectively gain of function, producing dominant negative
repressors. To identify the nature of the mutations found in HDLS,
equivalent murine Csf1r proteins were expressed in factor dependent
Ba/F3 cells. Expression of the wild-type receptor generated cells that
could survive and proliferate in CSF1 (Figure 2). FACS analysis
confirmed surface expression of Csf1r in these wild-type receptor
expressing cells (Figure 3A). Conversely, the four mutations
reported by Rademakers et al1 all produced cells that were unable
to survive in CSF1 (Figure 2) and therefore the four HDLS mutations
were cultured in IL-3. Because it was not possible to select for CSF1
dependence, not all cells were positive, but those that were
demonstrated the same level of surface receptor as cells expressing
wild-type receptor (Figure 3C).
Functional signaling depends on the mutation site within Csf1r.
We examined four other Csf1r mutations: K584E, V661I/T663A,
R814P and K614R, with the latter serving as a positive control for
loss of kinase activity. Like the HDLS mutants, the K614R mutant
receptor could not survive in CSF1 alone in Ba/F3 cells (Figure 2), yet
still expressed Csf1r on the surface (Figure 3B). To further validate
the hypothesis that conserved amino acids within the catalytic site
are important for autoinhibition, we produced a double mutation
within the active site (V661I/T663A) that was not predicted to
impact kinase activity. This double mutant demonstrated a small
but statistically significant amount of constitutive activity in
promoting survival and proliferation of Ba/F3 cells in the absence
of growth factors (Figure 2). K584Ewas constitutively active in Ba/F3
cells (Figure 2) and expressed Csf1r on the surface (Figure 3B) whilst
Ba/F3 cells expressing the activation loop mutation (R814P)
remained CSF1-dependent (Figure 2).
HDLS mutant Csf1r can bind CSF1, dimerize, and internalize.
Upon binding of its ligand, (Csf1 or IL-34) the Csf1 receptor dime-
rizes and following autophosphorylation of intracellular tyrosine
residues the receptor is internalized and eventually degraded22. We
have shown that the mutations in HDLS are unable to signal via Csf1r
in the presence of CSF1 yet still express Csf1r on the surface. To
confirm that loss of receptor kinase activity does not necessarily
affect receptor downregulation23 we co-treated the factor dependent
mutants with CSF1. In each case, addition of CSF1 down-regulated
surface CSF1R (Figure 3C).
Discussion
Csf1r regulates the proliferation, differentiation and survival of cells
of the mononuclear phagocyte lineage, which include the microglia
in the brain4. In this study we chose four CSF1Rmutations identified
in HDLS as well as a kinase defective mutation (K614R), a highly
conserved lysine mutation (K584E), an activation loop mutation
(R814P) and a double mutation (V661I/T663A) within the catalytic
site of the Csf1r protein kinase domain and created the equivalent
murine mutations.
The IL3-dependent Ba/F3 cell line24 was used to test the biological
activity ofmutant receptors.When wild type Csf1r is introduced into
these cells, survival can be maintained in the presence of CSF1 alone.
Autophosphorylation of Csf1r dimers in response to ligand binding
initiates recruitment of and activation of downstream signaling
molecules such Src15,25, Grb226, STAT proteins27 and PI3 kinase28.
Rademakers and colleagues1,2 found that CSF1 did not induce autop-
hosphorylation of the 3 HDLS mutant CSF1R (E633K, M766T, and
M875T) suggesting that they were kinase-dead, similar to K614A,
which fails to exhibit tyrosine phosphorylation or kinase activity14.
In keeping with this view, Ba/F3 expressing any of the HDLS
mutations (E631K, M764T, I792T and M873T) were unable to sur-
vive in CSF1. Nevertheless, the mutant proteins were on the cell
surface at similar levels to the wild type protein and were removed
from the surface in response to CSF1 (Figure 3), consistent with
previous evidence that receptor internalization does not require
CSF1R kinase activity29. These data demonstrate clearly that the
Figure 1 | Overlay of the murine (red) and human (blue) CSF1R
autoinhibited kinase domain shows significant sequence homology.
YASARA-predicted proteins show a sequence similarity of 95.74% and
RMSD of 0.365 A˚. Locations of the HDLS mutations1 are shown in yellow.
www.nature.com/scientificreports
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mutant receptors can form dimers and can bind CSF1. Hence, in
heterozygous individuals, 75% of ligand-receptor complexes would
be either mutant dimers, or wild-type mutant heterodimers. The
consequence would be a 75% reduction in the formation of active
CSF1-CSF1R dimers competent to signal upon addition of the
ligand. The inactive dimers are nevertheless internalized and degrad-
ed, so there is no possibility to recycle the wild-type proteins into
active complexes.
The intracellular domain of Csf1r is highly-conserved across spe-
cies. Our data suggest that there are many othermutations that could
Figure 2 | Mutations in the intracellular domain of mCsf1r resulted in either loss of Csf1r signalling or promoted factor independent survival in Ba/F3
cells. Untransfected Ba/F3 (naı¨ve) or Ba/F3 cells expressing wild-type or mutant mCsf1r were cultured alone or in either IL-3 or rhCSF1. The
mean of 3 experiments1 SEM is shown. P values were,0.0001 and,0.002 whenmutants were compared to wild-typemCsf1r growing in rhCSF1 (*) or
in no growth factor (#) respectively.
Figure 3 | Csf1r expression inmCsf1r Ba/F3 cells. (A) Flow cytometry analysis of Csf1r expression on naive and wild-typemCsf1r Ba/F3 cells cultured in
IL-3 or rhCSF1, respectively. (B) Left: Expression of Csf1r on naı¨ve cells cultured in IL-3 and onmutant cells capable of growth in rhCSF1; K584E, R814P
and V659I/T661A. Right: Expression of Csf1r on naı¨ve and K614R mutant cells cultured in IL-3. (C) Expression of Csf1r on mCsf1r mutant cells
cultured in IL-3 alone or both IL-3 and rhCSF1 compared to naı¨ve cells. All cells were gated on live cells as determined by negative staining for propidium
iodide.
www.nature.com/scientificreports
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act in a dominantmanner. In the autoinhibited CSF1R domain, E633
forms a salt bridge with the invariant amino acid K61612. Because
E633K was identified in HDLS patients, we generated a mutant
receptor in which K616 was mutated to arginine (K614R in mice)
to further test the importance of this interaction. The K616R mutant
is known to have reduced in vitro kinase activity14. Like the known
HDLS mutants it was unable to survive in CSF1, highlighting the
importance of the E633-K616 interaction in the autoinhibited
CSF1R. Rademakers and colleagues1 also identified two splice site
variants amongst the HDLS patients that generate in-frame deletions
of Exon 13 or Exon 18. Exon 13 is very highly conserved across
species, even in birds and fish. We tested K584E, a charge reversal
of an invariant amino acid within the exon 13-encoded region. This
mutation generated a constitutively-active receptor that could pro-
duce growth factor independent Ba/F3 cells. Previous studies used
another factor dependent cell line to identify activating mutations in
exon 18 of CSF1R. R802V was characterized, which is equivalent to
a known activating mutant in c-kit, a receptor tyrosine kinase
(RTK) that is a member of the same RTK subfamily as Csf1r30. The
R802V variant caused constitutive activation, and associated recep-
tor internalization and degradation31. Mutation of Asp814 in the
phosphotransferase domain of murine c-kit, has been shown to pro-
duce factor independent growth32. This amino acid is conserved in
Csf1r. Unexpectedly, this mutation had no effect on function; the
mutant receptor was able to sustain CSF1-dependent growth. We
hypothesize that a hydrophobic amino acid substitution would
have resulted in an activatingmutation.Morley and colleagues found
that substitution of human A802 with a polar residue could not
transform FDC-P1 cells31. Conserved amino acids within the cata-
lytic site of Csf1r are considered to be important for autoinhibition.
We produced a doublemutationwithin the active site, V661I/T663A.
Cells expressing the mutant grew in CSF1 but also displayed a
small, but statistically significant level of constitutive activity in the
absence of growth factors. T663 has been identified as a ‘Gatekeeper
Residue,’ an amino acid located in a kinase active site which confers
selectivity for binding nucleotides. Mutation of gatekeeper residues
in kinases have been shown to result in autoactivation due to
enhanced phosphorylation33.
The intracellular domain of the CSF1 receptor is highly conserved
across species, and indeed is closely-related to other receptor protein
tyrosine kinases6. The crystal structure of the autoinhibited kinase
domain revealed a very extensive interface between the JM domain
and the catalytic loop. Remarkably, the variation table for the CSF1R
gene in Ensembl identifies . 200 non-synonymous variants with
minor allele frequencies of 1/1000 ormore,many affecting conserved
amino acids in the intracellular domain. It appears likely that other
mutations in the receptor will be linked to more subtle microglial
defects, and perhaps to other macrophage-related pathologies. We
have demonstrated that mutations corresponding to those in HDLS
are required for the function of the mouse Csf1r. Csf1r signaling in
mice is known to be necessary for the generation of microglia4 and
there is some evidence that the receptor may contribute directly to
neuronal homeostasis34,35. The generation of the HDLS mutations in
the mouse germ line via ES cell mutagenesis may therefore generate
subtle hypomorphs and provide insight into neuroprotective roles of
Csf1r in the brain.
Methods
Cell culture. Untransfected Ba/F3 (naı¨ve) or Ba/F3 cells expressing wild-type or
mutant murine Csf1r were maintained in RPMI 1640 containing 10% FCS, 25 U/ml
penicillin, 25 mg/ml streptomycin and 2 mMGlutaMAXTM supplemented with either
5% conditioned media from x63-IL-3 cells36 or 104 U/ml (100 ng/ml) recombinant
human CSF1 (rhCSF1, a gift from Chiron, USA).
Plasmid construction and transfection. The wild type murine Csf1r and the
mutations K614R and V659I/T661A were amplified from plasmids provided by
Taconic using the following primers F: ACCATGGAGTTGGGGCCT and R:
GCAGAACTGGTAGTTGTTAGGCTG. The receptor sequences were subcloned
into pEF6/V5-His TOPO (Invitrogen). Murine mutations were prepared from the
wild type Csf1r pEF6/V5-His construct using Agilent’s QuikChange II XL Site-
Directed Mutagenesis kit according to instructions. The mutagenic primers are listed
in Table I with mutated nucleotides in bold and underlined. All clones were sequence
verified.
For generation of cells expressing wild-type or mutant mCsf1r, 53 106 Ba/F3 cells
were electroporated (1 pulse, 300 V, 975 mF, GenePulser, Bio-Rad) with 10 mg pEF6
in 250 ml completemedium. Stable transfectants were selected in 10 mg/ml Blasticidin
(Invitrogen).
Cell viability assays. 2 3 104 cells/well of a 96-well plate were plated in complete
medium either without growth factors, with x63-IL-3 conditionedmedia or 104 U/ml
(100 ng/ml) rhCSF1 and incubated at 37uC, 5% CO2 for 72 h. MTT stock solution
(5 mg/ml in PBS) was added directly to growth medium at a concentration of
0.5 mg/ml and the plate was incubated at 37uC for 3 h. Solubilization of tetrazolium
salt was achieved with a solution of 10% SDS/50% isopropanol/0.01 M HCl at 37uC
overnight. The plates were read at 570 nm with a reference wavelength of 650 nm.
FACS analysis. Cells capable of growth in rhCSF1 (wild-type Csf1r, K584E, R814P
and V659I/T661A) were starved of rhCSF1 24 hours prior to FACS analysis to allow
for cell surface expression of the receptor. Cells unable to grow in rhCSF1 (K614R and
the four HDLS mutants) were cultured in IL-3 prior to FACS analysis. Live cells were
stained for Csf1r expression with anti-Mouse CD115 (c-fms) PE (eBioscience)
according to standard protocols and analysed on a FACS Calibur (BD). Dead cells
were excluded with propidium iodide staining (1 mg/ml). For analysis of cell surface
Csf1r downregulation, HDLS mutants were cultured in IL-3 and were also co-treated
with rhCSF1 for 4 h prior to analysis.
Protein visualization. YASARA (http://www.yasara.org/) was used to predict the
structure of the murine (aa540–917) and human (aa542–919) autoinhibited kinase
domain based on the human crystallized structure (PDB ID code 2OGV) reported by
Walter and colleagues12. Our models include the kinase insert domain which was
omitted from 2OGV. Both proteins were aligned using MUSTANG37.
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